Ozempic and Wegovy are the same molecule, semaglutide, sold under different brands for different approved indications and doses. The trial evidence relevant to longevity claims belongs to the molecule and the GLP-1 agonist class, and the SELECT trial specifically used the Wegovy formulation and dose.
Ozempic and Wegovy are both semaglutide, manufactured by the same company, differing in approved indication (Ozempic: type 2 diabetes; Wegovy: chronic weight management) and typically in maximum approved dose (Wegovy is approved up to a higher dose than Ozempic's standard diabetes titration).
This matters directly for interpreting the SELECT trial, the landmark cardiovascular outcome trial most often cited in longevity discussions of GLP-1 agonists: SELECT specifically used the Wegovy formulation and dose (2.4mg weekly) in adults with established cardiovascular disease and overweight or obesity but without diabetes — not the Ozempic diabetes-dosing regimen, and not a diabetic population.
SELECT (2023) reported a hazard ratio of 0.80 (95% CI 0.72–0.90) for major adverse cardiovascular events (MACE) — a real, Phase III, hard-outcome result, and the primary basis for GLP-1 agonists' Strong evidence tier on Geroevidence. This is genuinely one of the strongest outcome-level results tracked for any intervention on the index, non-diabetic population specifically.
Because SELECT enrolled a non-diabetic, cardiovascular-disease-plus-overweight population using the Wegovy dose, its result does not directly generalize to a diabetic population using Ozempic dosing, or to a metabolically healthy, normal-weight population using either drug off-label — both are reasonable but distinct extrapolations beyond what the trial itself demonstrated.
A recurring pattern in GLP-1 media coverage is citing SELECT's cardiovascular result as generic support for "Ozempic" or "semaglutide" broadly, without noting the specific dose, formulation, and population it was tested in. The result is real and important — it just applies most directly to the population and dosing regimen actually studied.
Ozempic and Wegovy share a molecule and a drug class with genuinely strong hard-outcome cardiovascular evidence (SELECT). That specific trial result belongs to the Wegovy dose and formulation, in a non-diabetic, cardiovascular-disease-plus-overweight population — a detail worth knowing before extrapolating the finding to a different dose, drug, or population.
This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.